Tampere University participates in a project that is developing treatments for COVID-19
The project will validate a biomarker and artificial intelligence-assisted treatment using a promising drug called FX06.
The study is investigating the impact of COVID-19 on endothelial cells and the potential protective effect of FX06. The study will use omics technologies, produce new algorithms and opensource software for data analysis and modelling as well as develop health economics models that can help to ensure the benefits and cost-effectiveness of care.
“We are involved in the project’s AI application trial,” says Alpo Värri, Research Director at the Faculty of Medicine and Health Technology.
“With the patient registration data we are collecting, we aim develop models to support the decision-making of persons caring for COVID patients,” Värri adds. The models being developed will be made openly available once their functionality has been verified.
At Tampere University, the project partners include Professor Mark van Gils, Research Director Alpo Värri and Project Manager Antti Kallonen.
The multidisciplinary consortium encompasses 17 partners from 13 European countries. Researchers of cell biology, information technology, pharmaceuticals, economics, social sciences, and clinical researchers are involved.
The European Union funds the three-year consortium by €10 million. Professor Kai Zacharowski from Frankfurt University Hospital coordinates the project.
Photo: CDC / Unsplash & Jonne Renvall / Tampereen yliopisto
